Eligible Medications
ViiVConnect offers savings and assistance programs for patients who are insured, underinsured, and uninsured. Learn more below about ViiV Healthcare medications that are eligible for savings and assistance.
APRETUDE
Savings Program*
Extended-release injectable suspensions: cabotegravir 200 mg/mL
Up to $7850 per year
eVoucherRx™*
Extended-release injectable suspensions: cabotegravir 200 mg/mL
Up to $7850 per yer
Patient Assistance Program (PAP)*
Extended-release injectable suspensions: cabotegravir 200 mg/mL
CABENUVA
Savings Program*
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
Up to $13,000 per year
eVoucherRx™*
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
Up to $13,000 per year
Patient Assistance Program (PAP)*
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
(dolutegravir and lamivudine)
ViiVConnect Savings Card*
Tablets: 50 mg dolutegravir and 300 mg lamivudine
Up to $6250 per year with no monthly limit†
eVoucherRx™*
Tablets: 50 mg dolutegravir and and 300 mg lamivudine
Up to $6250 per year with no monthly limit†
Patient Assistance
Program (PAP)*
Tablets: 50 mg dolutegravir and 300 mg lamivudine
Patient Assistance Program (PAP)*
Tablets: 150 mg
Tablets: 300 mg
Oral Solution: 10 mg/mL
ViiVConnect
Savings Card*
Tablets: 50 mg dolutegravir and 25 mg rilpivirine
Up to $6250 per year with no monthly limit†
eVoucherRx™*
Tablets: 50 mg dolutegravir and and 25 mg rilpivirine
Up to $6250 per year with no monthly limit†
Patient Assistance Program (PAP)*
Tablets: 50 mg dolutegravir and 25 mg rilpivirine
Patient Assistance Program (PAP)*
Capsules: 100 mg
Oral Solution: 10 mg/mL
Injection, for Intravenous use:
10 mg/mL (20 mL vial)
ViiVConnect
Savings Card*
Extended-Release Tablets: 600 mg
Up to $7500 per year with no monthly limit†
eVoucherRx™*
Extended-Release Tablets: 600 mg
Up to $7500 per year with no monthly limit†
Patient Assistance Program (PAP)*
Extended-Release Tablets: 600 mg
Patient Assistance Program (PAP)*
Tablets: 150 mg
Tablets: 300 mg
ViiVConnect
Savings Card*
Tablets: 50 mg
Up to $5000 per year with no monthly limit†
eVoucherRx™*
Tablets: 50 mg
Up to $5000 per year with no monthly limit†
Patient Assistance Program (PAP)*
Tablets: 50 mg
TIVICAY PD
ViiVConnect
Savings Card*
Tablets for Oral Suspension: 5 mg
Up to $5000 per year with no monthly limit†
eVoucherRx™*
Tablets for Oral Suspension: 5 mg
Up to $5000 per year with no monthly limit†
Patient Assistance Program (PAP)*
Tablets for Oral Suspension: 5 mg
TRIUMEQ
ViiVConnect
Savings Card*
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
Up to $7500 per year with no monthly limit†
eVoucherRx™*
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
Up to $7500 per year with no monthly limit†
Patient Assistance Program (PAP)*
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
TRIUMEQ PD
ViiVConnect
Savings Card*
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
Up to $7500 per year with no monthly limit†
eVoucherRx™*
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
Up to $7500 per year with no monthly limit†
Patient Assistance Program (PAP)*
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
Patient Assistance Program (PAP)*
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
Subject to eligibility, program terms, and conditions. ViiVConnect programs do not constitute health insurance.
Total savings not to exceed $7500 per year. Restrictions apply. Offer limited to 1 per person.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
CBTWCNT230004
